These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1420748)

  • 1. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis.
    Hendel L; Hage E; Hendel J; Stentoft P
    Aliment Pharmacol Ther; 1992 Oct; 6(5):565-77. PubMed ID: 1420748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis.
    Hendel L
    Aliment Pharmacol Ther; 1991 Oct; 5(5):471-80. PubMed ID: 1793779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.
    Armstrong D
    Lancet; 2000 Aug; 356(9230):610-2. PubMed ID: 10968429
    [No Abstract]   [Full Text] [Related]  

  • 4. The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole.
    Shoenut JP; Wieler JA; Micflikier AB
    Aliment Pharmacol Ther; 1993 Oct; 7(5):509-13. PubMed ID: 8280819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux.
    Robinson M; Maton PN; Allen ML; Humphries TJ; McIntosh D; Cagliola AJ; Bradstreet TE
    Aliment Pharmacol Ther; 1991 Dec; 5(6):645-51. PubMed ID: 1782307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
    Havelund T; Laursen LS; Lauritsen K
    Scand J Gastroenterol Suppl; 1994; 201():69-73. PubMed ID: 8047827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
    Klinkenberg-Knol EC; Nelis F; Dent J; Snel P; Mitchell B; Prichard P; Lloyd D; Havu N; Frame MH; Romàn J; Walan A;
    Gastroenterology; 2000 Apr; 118(4):661-9. PubMed ID: 10734017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
    Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
    Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole.
    Klinkenberg-Knol EC; Meuwissen SG
    Aliment Pharmacol Ther; 1990 Oct; 4(5):485-95. PubMed ID: 2129636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
    Carlsson R; Dent J; Watts R; Riley S; Sheikh R; Hatlebakk J; Haug K; de Groot G; van Oudvorst A; Dalväg A; Junghard O; Wiklund I
    Eur J Gastroenterol Hepatol; 1998 Feb; 10(2):119-24. PubMed ID: 9581986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of omeprazole treatment in gastro-oesophageal reflux disease.
    Hendel J; Hendel L; Hage E; Hendel J; Aggestrup S; Nielsen OH
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):417-20. PubMed ID: 8804867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical treatment of gastro-oesophageal reflux disease.
    De Giorgi F; Savarese MF; Atteo E; Leone CA; Cuomo R
    Acta Otorhinolaryngol Ital; 2006 Oct; 26(5):276-80. PubMed ID: 17345932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
    Hage E; Hendel L; Gustafsen J; Hendel J
    Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial.
    Wu JC; Chan FK; Ching JY; Leung WK; Hui Y; Leong R; Chung SC; Sung JJ
    Gut; 2004 Feb; 53(2):174-9. PubMed ID: 14724146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.